Mechanisms of photosensitization induced by drugs: A general survey

Mecanismos de fotosensibilización inducida por fármacos: Una visión general

QUINTERO, B. (*) AND MIRANDA, M. A. (**) 

(*) Dpt. Química Física. Facultad de Farmacia. Campus de Cartuja. Universidad de Granada. 18071 Granada. Spain. E-mail: bqosso@platon.ugr.es 


ABSTRACT

This paper presents a general survey of the mechanisms involved in drug phototoxicity. Moreover, a list of 174 currently used clinical drugs inducing photosensitization is provided in addition to some others from which phototoxic effects are suspected. Likewise, some aspects related to the mechanisms involved in the phototoxicity of fluoroquinolones and non steroidal-antiinflammatory drugs have been reviewed. Finally, a possible role of the arenediazonium ions as photosensitisers is discussed.


RESUMEN

En el presente trabajo se hace ofrece una visión general los mecanismos relacionados con la fototoxicidad de sustancias farmacológicamente activas. Además se ha confeccionado una lista de 174 compuestos utilizados en la actualidad en la práctica clínica y de los que se existe pruebas de su actividad fototóxica. Conjuntamente se ofrece otra relación con sustancias cuyos efectos fototóxicos se sospechan. Asimismo, se revisan algunos aspectos relacionados con los mecanismos de fotosensibilidad de fluoroquinolonas y antiinflamatorios no esteroides. Por último, se discute la posible actividad fotosensibilizadora de los iones arenediazonínicos


INTRODUCTION

The treatment of deseases requires occasionally the use of either systemic or topical medication during certain period of time. Frequently the treatment coincides with exposures to electromagnetic radiations coming from different types of sources (sunlight in works made outdoor, or in vacational seasons, intense artificial radiations used in specific works, etc.). That coincidence may lead to the appearance of unexpected effects varying from just a simple rash to severe cutaneous affectionations. Moreover other problems may also arise from the damage of internal organs following the drug-radiation interaction.

Interaction between the electromagnetic radiation and the matter encompasses a great number of events among which photophysical and photochemical processes can be included. Those reactions which involve UV/Vis radiation and biological systems are particularly interesting because of their wide field of applications.
(environmental, energetic, biological...). One of the biological applications is the photosensitization phenomena. Photosensitization reactions is a continuously growing area of research which deals with the desirable and undesirable processes induced in biological systems by the absorption of UV/Vis radiation (Beijersbergen van Henegouwen, 1997).

In general, photosensitization is an abnormally high reactivity of a biological substrate to artificial sources or natural sunlight providing, in principle, ineffective doses of UVA, UVB and Vis radiations. Photosensitization requires the presence in the biological medium of certain substances known as photosensitisers which induce the changes in the biological substrate after absorbing appropriate radiation (Beijersbergen van Henegouwen, 1981) (Spikes, 1989) (Miranda, 1992) (Spielmann et al, 1994). The photosensitisers structural requirements to induce phototoxicity are related with the ability for absorbing those radiation wavelengths which present a better skin penetration (above 310 nm) favouring the subsequent photochemical decomposition to form stable photoproducts, free radicals and/or singlet oxygen (Condorelli et al., 1996a). It is possible to find photosensitisers in the cellular content (e.g. flavins and porphyrins), in foods, cosmetics, some plants or their juices, industrial chemicals (dyes, coal tar, derivatives chlorinated hydrocarbons..) and drugs. In addition to so broad distribution, the exogenous photosensitisers may enter into the body through different ways as well: ingestion, inhalation, injection or direct contact with the skin or mucouses.

With regard to drugs, photosensitization reactions can be used in a therapeutic approach; i.e. photodynamic therapy (Henderson and Dougherty., 1992) (Dougherty and Marcus, 1992) (Szeimies et al., 1996), blood purification (Margolis-Nunno et al., 1996), inactivation of viruses (Sieber et al., 1992); or can appear as an adverse side-reaction. Biological targets for photosensitization are cell membranes, cytoplasm organelles and the nucleus (Epe, 1993) originating minor effects such as cutaneous reactions: erythema, pruritus, urticaria and rash or severe effects such as genetic mutations, melanoma, etc. which not always concern the light-exposed areas but may reach internal organs as well (Beijersbergen van Henegouwen, 1981) (Epstein, 1989). The symptoms following noxious photosensitization reactions appear immediately after the skin exposure and they will vary depending on the amount of radiation absorbed, type and amount of photosensitiser, skin type, and age and sex of the person exposed. It is worth noting that photosensitivity may occur in every person, usually presents dose-dependence and may not happen the first time the drug is taken. In that case the reaction, less common than phototoxicity, is known as photoallergy and is mediated by the binding to skin protein (Pendlington et al., 1990) (Lovell, 1993) (Castell et al., 1998) (Miranda et al., 1999). Moreover, a delayed phototoxic effect can also appear as a consequence of a reservoir of sensitiser or its metabolites which act even several days after the drug is not detectable in plasma.

The importance of the photosensitization processes can be easily understood taking into account the increasing number of reports dealing with phototoxic effects induced by new pharmaceuticals which may be explained on the basis of the different biological effects induced by the photoproducts in relation to their parents molecules. Photophysical and photochemical studies, including exam of excitation and emission properties, identification of reaction intermediates, isolation of photoproducts, analysis of interaction with biological substrates, are often an adequate approach to analyze the mechanisms through phototoxic effects can be produced. In the present article a brief overview is made regarding the mechanisms of photoxicity induced by drugs.

PHOTOSENSITIZATION MECHANISMS

Several authors (Foote, 1976, 1991), (Spikes, 1989), (Vargas et al., 1996) (Beijersbergen van Henegouwen, 1997) (Miranda, 1992, 1997) (Moore, 1998) reviewed chemical, medicinal and biological aspects of photosensitization reactions. The reaction starts with the radiation absorption by the photosensitiser which becomes electronically excited species. Usually the multiplicity of the excited state is one, so that the corresponding excited stated is named singlet...
state. The lifetime of the exited singlet state is very short (10^{-10} - 10^{-9} s). The monomolecular deactivation of the excited electronic states may occur by a radiative (fluorescence) or non-radiative processes (internal conversion or intersystem crossing). Intersystem crossing implies a change in multiplicity in a such way that the excited molecule is found in a so-called excited triplet state which has a much longer lifetime (10^{-6} - 10^{-3} s). Many photosensitization reactions proceed through a triplet state. So, a favoured intersystem crossing pathway must be expected for effective photosensitisers. Apart from the monomolecular pathway of deactivation for the excited photosensitiser (fluorescence, phosphorescence emission or non radiative deactivation), the fate of the photosensitisers in the excited state may be very different depending on the solvent, photosensitiser concentration, energy absorbed by the photosensitiser, type of substrate, proximity of substrate and photosensitiser, aerobic or anaerobic conditions, pH...

Four pathways are usually considered available for the excited photosensitisers ($Ph^*$) to exert phototoxic effects on some target in the biological substrate. First of all, an energy transfer [1] from excited triplet photosensitizer to the oxygen could produce excited singlet oxygen which might, in turn, participate in a lipid- and protein-membrane oxidation or induce a DNA damage.

\[
Ph^* + O_2 \rightarrow Ph + ^1O_2 \Rightarrow ^1O_2 + t\text{arg et} \quad [1]
\]

Second, an electron or hydrogen transfer could lead to the formation of free-radical species producing a direct attack on the biomolecules [2a] or in the presence of oxygen, to evolve towards secondary free radicals such as peroxyl radicals [2b] or the very reactive hydroxyl radical a known intermediate in the oxidative damage of DNA and other biomolecules. This latter pathway corresponds to successive reactions which involve the appearance of superoxide anion radical, its dismutation to form hydrogen peroxide followed with the hydrogen peroxide reduction to form hydroxyl radical. Generation of the radical takes place involving either the photosensitiser or the target biomolecule. These steps are outlined below [2c].

\[
\begin{align*}
Ph^* & \xrightarrow{\text{electron or hydrogen transfer}} Ph \cdot \Rightarrow Ph \cdot + t\text{arg et} \quad [2a] \\
Ph \cdot + O_2 & \rightarrow PhO_2 \cdot \Rightarrow PhO_2 \cdot + t\text{arg et} \quad [2b] \\
Ph \cdot + O_2 & \rightarrow Ph^+ \cdot + O_2^* \Rightarrow O_2^* \rightarrow H_2O_2 \rightarrow OH \cdot \Rightarrow OH \cdot + t\text{arg et} \quad [2c]
\end{align*}
\]

Usually the direct radical mediated-reactions are called Type I reactions whereas singlet oxygen–mediated reactions are considered Type II (Foote, 1991). Frequently Type I and Type II reactions occur simultaneously and it is difficult to separate the effects corresponding to each Type. However, an experimental procedure has been reported to facilitate the study of pure radical effects (Aveline et al., 1998)

Many photosensitization reactions may be explained on the basis of the mechanism Type I or Type II, but are also possible additional pathways. Thus, a covalent photobinding [3] between photosensitiser and one particular macromolecule could take place inducing cell damage as well.

\[
Ph^* + t\text{arg et} \rightarrow Ph - t\text{arg et} \quad [3]
\]

Finally, the photosensitiser could undergo a decomposition (probably via homolytic process) [4a-4b] so that the resulting photoproducts can act either as toxins or as new photosensitisers

\[
\begin{align*}
Ph^* + (\text{redutant or oxidant}) & \rightarrow Ph \cdot \rightarrow Photoproucts \Rightarrow \\
Photoproucts + t\text{arg et} & \quad [4a] \\
Photoproucts + hv & \rightarrow Photoproucts^* \Rightarrow Photoproucts^* + t\text{arg et} \quad [4b]
\end{align*}
\]
An illustrative example for these latter pathways may be found in the study of the reactivity of nifedipine [NIF] a nitroaromatic molecule used in the treatment of myocardial ischemia and hypertension (De Vries et al., 1995, 1998). UV and visible radiations transforms NIF into its nitroso derivative [NONIF] in the absence of glutathione. Moreover, NIF irradiated with UV and visible light in the presence of glutathione originates the lactam [NHNIF] acting NONIF as an intermediate according to the following scheme.

\[
\begin{align*}
\text{NIF} & \rightarrow \text{NONIF} \\
\text{NONIF} & \rightarrow \text{NHNIF}
\end{align*}
\]

\[\text{hv} \quad \text{GSH} \quad \text{NHNIF}\]

In vivo, after intravenous administration, NHNIF is rapidly (< 2 h.) cleared from the blood of rats and is excreted almost quantitatively via the bile, but in the HPLC exam of extracts of bile after the administration of NONIF or NIF (followed by UVA-exposure of the rat) less than 5% of initial concentration inoculed was detected as NHNIF plus a photoproduct derived from NHNIF. In principle, these results indicated that photoproduct can affect internal organs in the body. Besides, the results also suggested that, unlike NHNIF, a possible interaction with biomacromolecules could be expected for NONIF or NIF (in rat exposed to UVA radiation).

In addition, NIF, NONIF and NHNIF can be recovered quantitatively by one extraction with chloroform from aqueous solutions so that a similar lipophilicity is expected for all of them. Therefore no difference in capacity to complex protein present in the bovine serum albumine should be expected. However, samples of bovine serum albumine incubated with either NIF, NONIF and NHNIF in the dark or irradiated by UVA, analyzed by HPLC after extracting with chloroform showed recoveries near to 100% for NHNIF. At the contrary recoveries about 43-45% were obtained from the samples of bovine serum albumine incubated with either NIF and irradiated with UVA light or NONIF in the dark. These results agree well with the formation of an irreversible binding to biomacromolecules of NIF and its primary photoproduct NONIF. In this way, side effects of nitroaromatic nifedipine could in part be attributed to photoactivation of NIF which may be in competition with the enzymatic reduction of the nitro group.

DRUGS AS PHOTSENSITISERS

In Table I is shown a non-exhaustive collection of phototoxic drugs pertaining to different therapeutic classes, i.e.; Antibiotics, Anti-diabetic drugs, Antihistamines, Cardiovascular drugs, Diuretics, Non-steroidal anti-inflammatory drugs (NSAIDs), Psychiatric drugs and others. The collected drugs appear in the literature as phototoxic either in vivo or in vitro. No consideration about its phototoxic potency has been made therefore potent phototoxic drugs are presented in Table I together with others inducing low phototoxic effects or, being potentially phototoxic, are currently under investigation. Photodynamic therapy (PDT) and PUVA-therapy photosensitisers have not been included otherwise they have an additional therapeutic use. The bibliographic sources used appear in the bottom of the Table I. In Table II appears some drugs for which phototoxic effects are suspected or exist, at least, one report claiming such phototoxic effects
### TABLE I

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Therapeutic use*</th>
<th>Drug name</th>
<th>Therapeutic use*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetazolamide</td>
<td>Diuretic</td>
<td>Isoniazid</td>
<td>Antibacterial</td>
</tr>
<tr>
<td>Acetohexamide</td>
<td>Antidiabetic</td>
<td>Isothiopendyl</td>
<td>Antihistaminic</td>
</tr>
<tr>
<td>Afloqualone</td>
<td>Muscular relaxant</td>
<td>Isotretinoin</td>
<td>Anti-acne</td>
</tr>
<tr>
<td>Alimezine</td>
<td>Neuroleptic</td>
<td>Ketoprofen</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td>Alprazolam</td>
<td>Tranquillizer</td>
<td>Levofoxacin</td>
<td>Antibiotic</td>
</tr>
<tr>
<td>Amiloride</td>
<td>Diuretic</td>
<td>Levomepromazine</td>
<td>Neuroleptic</td>
</tr>
<tr>
<td>Amiodarone</td>
<td>Coronary vasodilator</td>
<td>Lomefoxacin</td>
<td>Antibiotic</td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>Antidepressant</td>
<td>Loxapine</td>
<td>Tranquillizer</td>
</tr>
<tr>
<td>Amobarbital</td>
<td>Hipnotic</td>
<td>Maprotiline</td>
<td>Antidepressant</td>
</tr>
<tr>
<td>Amodiaquine</td>
<td>Antimalarial</td>
<td>Mefloquine</td>
<td>Antimalarial</td>
</tr>
<tr>
<td>Amoxapine</td>
<td>Antidepressant</td>
<td>Mequitazine</td>
<td>Antihistaminic</td>
</tr>
<tr>
<td>Bendroflumethiazide</td>
<td>Diuretic</td>
<td>Methazolamide</td>
<td>Diuretic</td>
</tr>
<tr>
<td>Benzthiazide</td>
<td>Diuretic</td>
<td>Methildilazine</td>
<td>Antipruritic</td>
</tr>
<tr>
<td>Benzydamide</td>
<td>Anti-inflammator</td>
<td>Methotrexate</td>
<td>Antineoplastic</td>
</tr>
<tr>
<td>Bithionol</td>
<td>Anti-infective</td>
<td>Methiclothiazide</td>
<td>Diuretic</td>
</tr>
<tr>
<td>Bromochlorosalicylanilide</td>
<td>Antifungal</td>
<td>Methyl dopa</td>
<td>Anti hypertensive</td>
</tr>
<tr>
<td>Buclozamide</td>
<td>Antifungal</td>
<td>Metolazine</td>
<td>Diuretic</td>
</tr>
<tr>
<td>Captopril</td>
<td>Antihypertensive</td>
<td>Minocycline</td>
<td>Antibacterial</td>
</tr>
<tr>
<td>Carbamatopine</td>
<td>Analgesic</td>
<td>Nabumetone</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td>Carbutamide</td>
<td>Antidiabetic</td>
<td>Nalidixic acid</td>
<td>Antibacterial</td>
</tr>
<tr>
<td>Carprofen</td>
<td>Anti-inflammator</td>
<td>Naprofen</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td>Chloridiazepoxide</td>
<td>Tranquillizer</td>
<td>Nifedipine</td>
<td>Hypotensor</td>
</tr>
<tr>
<td>Chloroquine</td>
<td>Antimalarial</td>
<td>Norfloxacin</td>
<td>Antibiotic</td>
</tr>
<tr>
<td>Chlorothiazide</td>
<td>Diuretic</td>
<td>Nor triptyline</td>
<td>Antidepressant</td>
</tr>
<tr>
<td>Chlorpromazine</td>
<td>Tranquillizer</td>
<td>Ofloxacin</td>
<td>Antibiotic</td>
</tr>
<tr>
<td>Chlorpropamide</td>
<td>Antidiabetic</td>
<td>Orbifloxacin</td>
<td>Antibiotic</td>
</tr>
<tr>
<td>Chlorprothixene</td>
<td>Neuroleptic</td>
<td>Oxomemazine</td>
<td>Antihistaminic</td>
</tr>
<tr>
<td>Chlorotetracycline</td>
<td>Antibacterial</td>
<td>Oxytetracycline</td>
<td>Antibacterial</td>
</tr>
<tr>
<td>Chloethalidone</td>
<td>Diuretic</td>
<td>Paroxetine</td>
<td>Antipsycotic</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>Antibiotic</td>
<td>Pentobarbital</td>
<td>Hypnotic</td>
</tr>
<tr>
<td>Clinafoxacin</td>
<td>Antibiotic</td>
<td>Perazine</td>
<td>Neuroleptic</td>
</tr>
<tr>
<td>Clofazimine</td>
<td>Antibacterial</td>
<td>Perfloxacin</td>
<td>Antibiotic</td>
</tr>
<tr>
<td>Clofibrate</td>
<td>Antilipidemic</td>
<td>Periciazine</td>
<td>Antipsycotic</td>
</tr>
<tr>
<td>Clomipramine</td>
<td>Antidepressant</td>
<td>Perphenazine</td>
<td>Antipsycotic</td>
</tr>
<tr>
<td>Clozapine</td>
<td>Sedative</td>
<td>Phenothiazine</td>
<td>Antipsychotic</td>
</tr>
<tr>
<td>Dacarbazine</td>
<td>Antineoplastic</td>
<td>Phenylbutazone</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td>Dantrolene</td>
<td>Muscle relaxant</td>
<td>Phenytoin</td>
<td>Anticonvulsant</td>
</tr>
<tr>
<td>Dapsone</td>
<td>Antibacterial</td>
<td>Piroxicam</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td>Demeclocycline</td>
<td>Antibacterial</td>
<td>Polythiazide</td>
<td>Diuretic</td>
</tr>
<tr>
<td>Demethylchlorotetracycline</td>
<td>Antibacterial</td>
<td>Procilulporazine</td>
<td>Anti-emetic</td>
</tr>
<tr>
<td>Desipramine</td>
<td>Antidepressant</td>
<td>Promazine</td>
<td>Tranquillizer</td>
</tr>
<tr>
<td>Diclofenac</td>
<td>Anti-inflammatory</td>
<td>Promethazine</td>
<td>Antihistaminic</td>
</tr>
</tbody>
</table>

*Therapeutic uses are based on common clinical applications and may vary depending on the specific drug and context.*
<table>
<thead>
<tr>
<th>Drug name</th>
<th>Therapeutic usea</th>
<th>Drug name</th>
<th>Therapeutic usea</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diflunisal</td>
<td>Anti-inflammatory.</td>
<td>Propiomazine</td>
<td>Anti-histaminic</td>
</tr>
<tr>
<td>Diliazem</td>
<td>Vasodilator</td>
<td>Prothipendyl</td>
<td>Neuroleptic</td>
</tr>
<tr>
<td>Dimethothiazine</td>
<td>Antihistaminic</td>
<td>Protriptyline</td>
<td>Antidepressant</td>
</tr>
<tr>
<td>Diphenhydramide</td>
<td>Antihistaminic</td>
<td>Pyrazinamide</td>
<td>Antibacterial</td>
</tr>
<tr>
<td>Dothiepin</td>
<td>Antidepressant</td>
<td>Quinacrine</td>
<td>Antimalarial</td>
</tr>
<tr>
<td>Doxepin</td>
<td>Antidepressant</td>
<td>Quinine</td>
<td>Antimalarial</td>
</tr>
<tr>
<td>Doxycycline</td>
<td>Antibacterial</td>
<td>Quinidine</td>
<td>Antiarrhythmic</td>
</tr>
<tr>
<td>Enalapril</td>
<td>Hypotensor</td>
<td>Risperidone</td>
<td>Anxiolytic</td>
</tr>
<tr>
<td>Enoxacin</td>
<td>Antibiotic</td>
<td>Rufloxacin</td>
<td>Antibiotic</td>
</tr>
<tr>
<td>Etretilate</td>
<td>Treatm. Psoriasis</td>
<td>Secobarbital</td>
<td>Hynotic</td>
</tr>
<tr>
<td>Felbamate</td>
<td>Antiepileptic</td>
<td>Sertraline</td>
<td>Antipsycotic</td>
</tr>
<tr>
<td>Felodipine</td>
<td>Hypotensor</td>
<td>Silver sulfadiazine</td>
<td>Antibacterial</td>
</tr>
<tr>
<td>Fenofostrate</td>
<td>Antilipidemic</td>
<td>Sitafloxacin</td>
<td>Antibiotic</td>
</tr>
<tr>
<td>Fenticlor</td>
<td>Fungicide</td>
<td>Sparfloxacn</td>
<td>Antibiotic</td>
</tr>
<tr>
<td>Flecainide</td>
<td>Antiarrhythmic</td>
<td>Sulfamethoxazole</td>
<td>Antibacterial</td>
</tr>
<tr>
<td>Floxacin</td>
<td>Antibiotic</td>
<td>Sulfanylamide</td>
<td>Antibacterial</td>
</tr>
<tr>
<td>Floxuridine</td>
<td>Antineoplastic</td>
<td>Sulfasalazine</td>
<td>Antibacterial</td>
</tr>
<tr>
<td>Fluorouracil</td>
<td>Antineoplastic</td>
<td>Sulfisoxazole</td>
<td>Antibacterial</td>
</tr>
<tr>
<td>Flutamide</td>
<td>Antineoplastic</td>
<td>Suprofen</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>Antidepressant</td>
<td>Terfenadine</td>
<td>Antihistaminic</td>
</tr>
<tr>
<td>Fluphenazine</td>
<td>Antipsychotic</td>
<td>Tetrachlorosalicylanilide</td>
<td>Germicide</td>
</tr>
<tr>
<td>Furosemide</td>
<td>Diuretic</td>
<td>Tetracycline</td>
<td>Antibacterial</td>
</tr>
<tr>
<td>Glibormuride</td>
<td>Antidiabetic</td>
<td>Thiazide</td>
<td>Diuretic</td>
</tr>
<tr>
<td>Gliclazide</td>
<td>Antidiabetic</td>
<td>Thiazimaniun</td>
<td>Antihistaminic</td>
</tr>
<tr>
<td>Glimepiride</td>
<td>Antidiabetic</td>
<td>Thiethylperazine</td>
<td>Antihistaminic</td>
</tr>
<tr>
<td>Glipizide</td>
<td>Antidiabetic</td>
<td>Thioproperazine</td>
<td>Neuroleptic</td>
</tr>
<tr>
<td>Glipizone</td>
<td>Antidiabetic</td>
<td>Thioridazine</td>
<td>Antipsychotic</td>
</tr>
<tr>
<td>Glitazide</td>
<td>Antidiabetic</td>
<td>Thiothixene</td>
<td>Antipsychotic</td>
</tr>
<tr>
<td>Glisoxepide</td>
<td>Antidiabetic</td>
<td>Tiapropenic acid</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td>Glyburide</td>
<td>Antidiabetic</td>
<td>Tolazamide</td>
<td>Antidiabetic</td>
</tr>
<tr>
<td>Glycopyramide</td>
<td>Antidiabetic</td>
<td>Tolbutamide</td>
<td>Antidiabetic</td>
</tr>
<tr>
<td>Glycylamide</td>
<td>Antidiabetic</td>
<td>Tolmetin</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td>Grepaflaxacin</td>
<td>Antibiotic</td>
<td>Trazodone</td>
<td>Antidepressant</td>
</tr>
<tr>
<td>Grisofulvin</td>
<td>Antifungal antibiotic</td>
<td>Tretinoin</td>
<td>Anti-acne</td>
</tr>
<tr>
<td>Haloperidol</td>
<td>Antidyskinetic</td>
<td>Triamterene</td>
<td>Diuretic</td>
</tr>
<tr>
<td>Hexachlorophene</td>
<td>Germicide</td>
<td>Trichlormethiazide</td>
<td>Diuretic</td>
</tr>
<tr>
<td>Hydralazine</td>
<td>Vasodilator</td>
<td>Triclosan</td>
<td>Germicide</td>
</tr>
<tr>
<td>Hydrochlorothiazide</td>
<td>Diuretic</td>
<td>Trifluoperazine</td>
<td>Antipsychotic</td>
</tr>
<tr>
<td>Hydroflumethiazide</td>
<td>Antihypertensive</td>
<td>Triflupromazine</td>
<td>Antipsychotic</td>
</tr>
<tr>
<td>Hydroxychloroquine</td>
<td>Antimalarial</td>
<td>Trimeprazine</td>
<td>Antipruritic</td>
</tr>
<tr>
<td>Hydroxyethylpromethazine</td>
<td>Antihistaminic</td>
<td>Trimethoprim</td>
<td>Antibacterial</td>
</tr>
</tbody>
</table>
Among the phototoxic drugs in Table I, two groups have received special attention, namely quinolone antibiotics and non-steroidal anti-inflammatory drugs.

Quinolone antibiotics bearing fluorine substituent are commonly called fluoroquinolones (FQ). In despite of some adverse side-effects on which several reviews have been published recently (Ball et al., 1995; 1999) (Stahlmann et al., 1999) (Lipsky et al., 1999), the promising therapeutic activities shown by these compounds have encouraged the development of up to three generations of FQ. Chemically the parent compound is nalidixic acid. Some derivatives maintain the naphtyridinecarboxylic nucleus (enoxacin, trovafloxacin) but in others is replaced by the quinolinecarboxylic acid (norfloxacin, lomefloxacin, sparfloxacin, clinafloxacin, ciprofloxacin) in both cases the nucleus is substituted with halogens in one or two positions. Also is common the presence of piperazynil group as a substituent.

**TABLE II**

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Therapeutic use*</th>
<th>Drug name</th>
<th>Therapeutic use*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amantadine</td>
<td>Antiviral.</td>
<td>Losartan</td>
<td>Hypotensor</td>
</tr>
<tr>
<td>Azithromycin</td>
<td>Antibacterial.</td>
<td>Meclofenamic acid</td>
<td>Anti-inflammatory</td>
</tr>
<tr>
<td>Astemizole</td>
<td>Antihistaminic.</td>
<td>Mirtazapine</td>
<td>Antidepressant.</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>Immunosuppressant</td>
<td>Olsalazine</td>
<td>Gastric protector</td>
</tr>
<tr>
<td>Benzoicaine</td>
<td>Anaesthetic</td>
<td>Omeprazole</td>
<td>Gastric protector</td>
</tr>
<tr>
<td>Butabarbital</td>
<td>Sedative</td>
<td>Paramethadione</td>
<td>Anticonvulsant.</td>
</tr>
<tr>
<td>Carbinoxamine</td>
<td>Antihistaminic.</td>
<td>Phenelzine</td>
<td>Antidepressant.</td>
</tr>
<tr>
<td>Danazol</td>
<td>Androgen</td>
<td>Procaine</td>
<td>Local anesthetic</td>
</tr>
<tr>
<td>Dichlorphenamide</td>
<td>Carb.Anhyd.Inhibitor</td>
<td>Pyridoxine</td>
<td>Vitamin</td>
</tr>
<tr>
<td>Dipyrazine</td>
<td>Neuroleptic</td>
<td>Pyrimethamine</td>
<td>Antimalarial.</td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>Antifungal</td>
<td>Quinapril</td>
<td>ACE inhibitor.</td>
</tr>
<tr>
<td>Fluvoxamine</td>
<td>Antidepressant.</td>
<td>Salicylates</td>
<td>Analgesic.</td>
</tr>
<tr>
<td>Ganciclovir</td>
<td>Antiviral</td>
<td>Saquinavir</td>
<td>Antiviral.</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>Antifungal</td>
<td>Sotalol</td>
<td>Beta blocker.</td>
</tr>
<tr>
<td>Lincomycin</td>
<td>Antibacterial</td>
<td>Trimethadione</td>
<td>Anticonvulsant.</td>
</tr>
<tr>
<td>Lisinopril</td>
<td>Hypotensor</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FLUOROQUINOLONES**

In summary, the development and usage of FQs have been extensively surveyed, with the emphasis on their antimicrobial and anti-inflammatory properties. However, with the increasing number of reports on phototoxic reactions, it is crucial to understand the mechanisms underlying these side-effects to ensure patient safety and effective treatment.
This pharmacological class has a broad-spectrum against gram-positive or gram-negative bacteria (Neu, 1990). Newer FQ, such as clinafloxacin, grepafloxacin, levofloxacin, sparfloxacin, tosufloxacin and trovafloxacin, are characterized by markedly improved activity against Gram-positive bacteria, e.g. pneumococci and enterococci, and also better activity against organisms such as mycoplasmas and chlamydiae (Goldstein, 1996) (Norrby, 1997) (Andriole, 1999). FQ act on the bacterial topoisomerase DNA gyrase (Domagala et al., 1986) having been suggested that quinolones bind DNA-gyrase complex via a magnesium ion inhibiting bacterial growth (Palù et al., 1992). The indexes of tolerability to FQ, mainly in the third generation, is claimed to be very high so that there is no significant difference between FQ and other antimicrobials in most double-blind studies (Stahlmann et al., 1998). Thus, apart from the temafloxacin syndrome, it is considered that FQ adverse effects are usually mild and reversible (Ball et al., 1999).

Nevertheless, the therapeutic use of FQ is limited in part because of the side-phototoxic effects reported widely in the literature (see references cited in Fasani et al., 1998) and the photomutagenic and/or carcinogenic effects indicated in some cases (Chetalat et al., 1996) (Klecak et al., 1997) (Johnson et al., 1997) (Maekinen et al., 1997) (Urbach, 1997) (Reavy et al., 1997). Mutagenic effects induced by FQ have been reported even in the dark (Domagała, 1994). In general it can be assumed that phototoxicity has not to be a necessary factor regarding a possible photomutagenic risk (Loveday, 1996). In the case of FQ, some results obtained from the in vitro Chinese hamster V79 cells assay indicate a similar ranking for phototoxic and photomutagenic potencies (Snyder et al., 1999). Mutagenicity effects found for phototoxic FQ appears to indicate shared mechanistic routes. Thus, currently a number of works are made dealing with the mechanisms of photosensitization induced by FQ in an attempt to explain phototoxic and genotoxic effects.

Phototoxicity and photomutagenicity induced by FQ appears to be related with structural features (Ball et al., 1995) (Lietman, 1995). 8-Halogenated FQ (i.e., lomefloxacin, clinafloxacin) provoke severe reactions in the skin in comparison with the low phototoxicity exhibited by 8-methoxy derivatives (Marutani et al., 1993) (Domagała et al., 1994) (Rosen et al., 1997a). Moreover, fluorine substituent to the 8-position of quinoline ring of FQ also induces photoallergic responses (Marutani et al., 1998). In general, the presence of an electron-donating substituent has been suggested to confer photostability to the halogenated substituent at the position 8 reducing the phototoxicity (Yoshida et al., 1996). Although the exact mechanism of FQ photosensitization remains unclear, basically, the following processes have been indicated to justify the FQ photoreactivity: i) oxygen singlet produced by the zwitterionic form resulting from dissociation of carboxylic acid and simultaneous protonation of the piperazinyl group (Bilski et al., 1996). ii) the formation of reactive oxygen species including singlet oxygen, superoxide radical, hydroxyl radical and hydrogen peroxide (Wagai et al., 1991, 1992a, 1992b) (Iwamoto et al., 1992) (Rosen et al., 1997b) (Umezawa et al., 1997) (Morimura et al., 1997), although; a mechanism based on these toxic agents does not appear to be correlated with the FQ photoreactivity (Umezawa et al., 1997) (Martínez et al., 1998); iii) the dehalogenation photochemically induced generating a highly reactive carbene C-8 which reacts with some cell component (Martínez et al., 1997, 1998); iv) a combined process wherein the homolytic defluorination leading to the formation of aryl radical which triggers the attack to the cellular substrate whereas the oxygen reactive species could operate either in a secondary or in a parallel process (Fasani et al., 1998). Similar conclusion has been reported in the study of effects of
photoactivated lomefloxacin on cultured adult rat liver cells. In this case, 8-oxo-7,8-dihydro-2'-deoxyguanosine fomed is attributed to the simultaneous Type I and Type II photosensitization (Rosen, 1997c). The defluorination is believed to proceed via the triplet state corresponding to the zwitterionic species resulting from protonation of the piperazinyl group and the dissociation of carboxylic acid (Sortino et al., 1998). Identical point of view is adopted in the study of the photodegradation of rufloxacin (RFX) which presents a strong dependence on the pH (Condorelli et al., 1999). Moreover the presence of oxygen is proved to mediate in UVA-induced damage in membranes as observed in red blood cell hemolysis and lipid peroxidation. These results are interpreted in terms of simultaneous Type I (radical mediated) and Type II (oxygen mediated) reactions according to the following scheme (Condorelli et al., 1999).

An important aspect of this issue is the localization and the accessibility to the targets for the photosensitisers and/or the photoproducts. Thus, the structural and physicochemical properties, kinetic, metabolism and the photophysics and photochemistry of the photosensitisers are usually invoked to explain the molecular mechanism of phototoxicity in vitro. However, it has been claimed the influence of the biological environment on the phototoxicity mechanisms (Aveline et al. 1999).

In the same context, reactive oxygen species generated from the photoactivation of some FQ are proved to attack DNA (Snyder et al., 1999) or induce lysosomal membranes damage (Ouedraogo et al., 1999) but that only could occur assuming that those species are generated inside the cell at the site wherein exert its action. Therefore, cell permeation, hydrophobicity, metabolization and subsequent subcellular localization appear to be critical factors to contribute to phototoxicity.

NON-STEROIDAL ANTIINFLAMMATORY DRUGS (NSAIDS)

NSAIDs is a chemically heterogeneous group of drugs mainly used as antiinflammatory particularly in the treatment of rheumatic diseases. Basically, three sub-class may be considered simply taking as a reference chemical group present in the molecule, i.e.; carboxylic acids (salicylates, arylalkanoic acids and fenamates), pyrazoles and oxicams (Condorelli et al., 1996a). In any of these sub-class phototoxic and non-phototoxic molecules can be found. Thus, the different photoreactivity as a consequence of different structural patterns as well as the different phototoxic effects observed either in vivo or in vitro (Ljunggren, 1985a, 1985b) (Przybilla et al.,

Ars Pharmaceutica, 41:1; 27-46, 2000
Among the NSAIDs, those compounds containing arylpropionic acid in its chemical structure have a considerable importance because of its extent use. It has been pointed out that such a use in the clinical practice has led to multiplier the number of reports about noxious photo-induced effects. The result is the existence of a number mechanistic studies on this subject. Benoxaprofen (not included in Table I), one of the most studied NSAID arylpropionic derivative, presents so acute phototoxic effects which have contributed to the removal of this drug from the European market in 1982. Naproxen is other typical representative compound of NSAIDs arylpropionic acid sub-class. It causes skin photosensitivity and DNA photocleavage (Diffey et al., 1983) (Artuso et al., 1990, 1991) (Condorelli et al., 1995) (Giuffrida et al., 1995, 1996). Phototoxic effects have been also reported for other compounds included in this sub-class such as ketoprofen (Przybilla et al., 1987b) (Costanzo et al., 1989b) (Mozzanica et al., 1990) (Nabeya et al., 1995), suprofen (Kurumaji et al., 1990, 1991) (De Guidi et al., 1994) (Castell et al., 1994a, 1994b) (Miran-Üal et al., 1994), carprofen (Ljunggren, 1985a, 1985b) (Przybilla et al., 1987b) (De Ğuidi et al., 1993). The rest of sub-classes present photoreactivity although its incidence is significantly lower. Nevertheless, it is possible to find a number of works about the photosensitising properties of NSAIDs arylacetic group derivatives such as diclofenac (Ljunggren, 1985a, 1985b) (Przybilla et al., 1987a), pyrazol derivatives such as benzydamide (Motley et al., 1988) (Foti et al., 1992) (Goday et al., 1993). A particular case is tolmetin an arylacetic derivative for which there is any phototoxicity clinical report although it induces phototoxic effects in vitro (Giuffrida et al., 1995) (Boscá et al., 1998).

Several mechanistic aspects related to the photodecomposition of NSAIDs have been analyzed in the papers released since 1989 by the Department of Chemical Science in the University of Catania (Italy) (Costanzo et al., 1989a, 1989b) (De Guidi et al., 1993, 1994) (Giuffrida et al., 1995, 1996a, 1996b) (Condorelli et al., 1995). Likewise, a number of works dealing with the same subject have been made in the Department of Chemistry in the Polytechnic University of Valencia (Spain) including some in collaboration with other centers (Boscá et al., 1990, 1992, 1994, 1995, 1997) (Miranda et al., 1991) (Jiménez et al., 1997) (Encinas et al., 1998a, 1998b, 1998c) (Castell et al., 1992, 1994a, 1994b) (de Vries et al., 1997)

The photodegradation of relevant NSAIDs arylalkanoic derivative, naproxen, in aqueous neutral medium is characterized by the appearance of a solvated electron and a triplet state as proved by flash photolysis technique. So, two pathways are claimed to be responsible of the phototoxic effects (Miranda, 1992). The triplet state of photoexcited naproxen has been recognized as an effective singlet oxygen sensitizer. Besides, the solvated electron appears involved in the formation of free radical. In fact, ESR assays using spin trap MNP [2-methyl-nitroso-propane] indicate the presence of a H-MNP adduct and another C-centered radical. Those data have been interpreted by considering that decarboxylation is the first step in the photodegradation process (Moore et al., 1988) (Costanzo et al., 1989a) (Boscá et al., 1990) (Castell et al., 1993). The C-centered radical is considered to evolve to a peroxyl radical which degrades to first a secondary alcohol and then to the ketone as a final product. As included in cyclodextrin a marked predominance of alcohol over ketone has been reported (Jiménez et al. 1997). It must be considered that those photoproducts differentiate from the parent product with regard to its acidity. The photodegradation reaction changes the acidic functional group involves in the metabolization and clearance of naproxen. Affecting biotransformation and pharmacokinetic factors naproxen becomes a more hydrophobic compound with capability to link to hydrophobic areas such membranes wherein it exert its phototoxic effects (Moore, 1998) acting in a similar way to that reported for benoxaprofen photoproducts (Sik et al., 1983) (Kochevar et al., 1984). NSAID acetic derivative diclofenac [2-(2,6-dichloroanilino)phenylacetic acid] is lesser phototoxic than naproxen. Nevertheless, this drug

Ars Pharmaceutica, 41:1; 27-46, 2000
has received attention because of its wide use. A mechanistic study of the photodegradation is found in the recent literature (Encinas et al., 1998). The major photoproducts of diclofenac are carbazole derivatives (compounds 8Clcb and cb) presenting the chloro derivative (8Clcb) structural similarity with the phototoxic drug carprofen. In contrast to that found for naproxen the acid group remains in the diclofenac photoproducts.

![Diclofenac and 8Clcb](image)

The point arising from this system is whether the phototoxicity may be attributed to the chlorocarbazole compound (8Clcb) or the interaction with the biological substrate is originated by the free radical formed in the photodegradation of diclofenac.

Assays in vitro performed with Diclofenac and the photoproducts show positive photoxicity only for 8Clcb. Likewise, the analysis of the photophysical data are interpreted considering the participation of the triplet state of 8Clcb. Thermodynamic considerations as well as an observed quenching of triplet state as the concentration of 8Clcb is increased lead to formulate the formation of an excimer from which a radical ion could be formed. Dehalogenation is followed to yield an aryl radical and chloride anion. The results obtained in laser flash photolysis and ESR experiments seems to be in agreement with the mechanism suggested.

**MISCELLANEOUS. ARYLNITROSAMINES, ARYLAZODERIVATIVES, ARYLTRIAZENES AND ARYLHYDRAZINES**

Some arylnitrosamines (Wakabayashi et al.; 1989) (Ohshima et al., 1989), arylazoderivatives (Stiborova et al., 1990) (Chung et al., 1992), aryltriazenes (Malaveille et al., 1982), arylalkyltriazenes (Thust et al., 1991) (Smith et al., 1996) and arylhydrazines (Toth, 1975, 1977, 1993) (Parodi et al. 1981) (Lawson et al., 1985) are genotoxic agents and have in common their capability to be metabolized to arenediazonium ions (Stiborova et al., 1988a, 1988b) (Smith et al., 1988) (Ohshima et al., 1989) (Thust et al., 1991) (Walton et al., 1997).

The salts of arenediazonium ions (ArN$_2^+$) are versatile compounds widely used in chemical synthesis (Zollinger, 1994). Some arenediazonium ions might be formed from the reaction in acid medium between sodium nitrite and a susceptible substrate coming from dietary component (Ochiai et al., 1984) or drugs such as bamethan (Kikugawa et al., 1987), acetaminophen (Ohta et al., 1988), etilefrin (Kikugawa et al., 1989) or synephrine (Fernández-Liencres et al., 1993), therefore the formation of arenediazonium ions in vivo is not unlikely. Moreover, it is known that edible mushrooms (Agaricus bisporus) contains arenediazonium ions as well as several precursors including some arylhydrazines (Levenberg, 1962) (Ross, 1982) (Chauhan et al, 1984) (Toth et al., 1989).

Most reactions involving arenediazonium ions are nucleophilic addition and dedazionation

\[
ArN_2^+ + R \rightarrow Ar - N = N - R
\]

\[
ArN_2^+ \rightarrow (Ar) + N_2
\]
where the second reaction corresponds to the dediazoniation process which gives rise to the appearance of a reactive species (Ar) and releases dinitrogen.

\[
\begin{align*}
\text{ArN}_2^+ & \xrightarrow{\text{h} \nu / \Delta} \text{Ar}^+ + N_2 \\
\text{ArN}_2^+ & \xrightarrow{e^-} \text{Ar}^+ + N_2
\end{align*}
\]

The degradation of arenediazonium ions, known as dediazoniation, may occur via two types of mechanism, either heterolytic or homolytic. The latter requires the transfer of an electron from a reducing agent.

Both processes can occur simultaneously the heterolytic one can be activated thermal or photochemically whereas the second one is favoured by strong reductants (Galli, 1988).

Some aspects related with the electronic structure, dediazoniation mechanisms (García Meijide et al., 1998) (Glaser et al, 1999 and references cited therein) (Pazo Llorente et al., 1999) (Quintero et al., unpublished results) keep these subjects as active fields of research. In addition, the arenediazonium ions have demonstrated mutagenic effects and can also cause tumors in animals (Malaveille et al., 1982) (Ochiai et al., 1984) (Ames et al., 1987) (Ohta et al., 1988) (Ohshima et al., 1989) (Kikugawa et al., 1987, 1989, 1992) (Kato et al., 1992) (Lawson et al., 1995) (Toth et al., 1981, 1982, 1989, 1992, 1993, 1998) (Stiborova et al., 1999) but there is some discrepancy about the ultimate genotoxic agent. In this context, it has been suggested the possible direct action of arenediazonium ions (Chin et al., 1981) (Hung y Stock, 1982) (Koeppke et al., 1990) (Gannett et al., 1999). On the other hand, mutagenic and carcinogenic effects have been also attributed to aryl radicals formed in a homolytic reaction (Berh, 1989) (Griffiths et al., 1992) (Kikugawa et al., 1992) (Kato et al., 1992) (Hazlewood et al., 1995) (Lawson et al., 1995) (Hiramoto et al., 1995) (Gannett et al., 1996, 1997). Besides aryl cation originated in heterolytic dediazoniation has been also suggested as genotoxic agent (Malaveille et al., 1982).

It is worth noting that apparently arenediazonium ions could be considered as good candidates to behave as photosensitizers. Although the aromatic substituents have a strong influence on the reactivity of arenediazonium ions, in general, they are photolabile compounds which decompose by action of UVA-Vis radiations to give an aryl cation (Ando, 1978). The aryl cation is so highly reactive species which result difficult its detection (Gasper et al., 1995) (Steeken et al., 1998). Thus, in a physiological medium, aryl cation will react likely with water but it is also probable to react with other substrate present in their vicinity (Behr, 1989) (Ayra et al., 1993). In addition, arenediazonium ions could remain accumulated in plasma taking account their ability to form azo coupling adduct with tiroxine and histidine residues of proteins (Tracey et al., 1997). Moreover, arenediazonium ions have shown to be capable to induce the peroxidation of lipids (Einsele et al., 1987) (Preece et al., 1989).

Antineoplastic drugs, vinblastine, fluorouridine, fluorouracil, flutamide, methotrexate or dacarbazine are recognized as phototoxics. One of them, dacarbazine is an imidazole dimethyltriazen e [5-(3,3-dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide] introduced into clinical practice in the 1970s which remains as a reference drug in the treatment of metastatic melanoma. It is known that the light decomposes this compound originating photoproducts responsible of the phototoxic effects (Stevens et al., 1978) (Baird et al., 1978) (Horton et al., 1979). However a very little information is found in the literature with regard to the phototoxicity induced by precursors of arenediazonium ions. Antitumour drugs such as 3-(haloethyl)aryltriazenes (Lown et al., 1982), diaryltriazenes (Lassiani, et al., 1990), dimethylphenyltriazenes (Foster et al., 1993); antiprotozoal drug diminazene used in association with Pt as cytotoxic drug (González et al., 1997); hydrazine derivatives used as antithrombotic and vasodilating drugs (Rehse et al., 1998); phenylazo derivatives with antitubercular activity (Vazzana et al., 1993) are some examples of drugs which present chemical structures for which, in principle, a possible metabolization to arenediazonium ions could be expected.

All of the data mentioned above suggest that photostable precursors could afford the formation of arenediazonium ions. Subsequent photoinduced formation of reactive species from arenediazonium
ions could add unwanted interferences in a system wherein therapeutic and mutagenic effects can occur associated. The coincidence of therapeutic and mutagenic effects, common in several triazenes compounds (Curtis et al., 1984), and the lack of information about possible synergistic effects in mutagenic damage as a result of the combination of alkylating agent (Sanderson et al., 1996) are important difficulties for this kind of drugs to be used safely. In fact, distinguishing between metastatic tumour and secondary malignancies induced by antitumour agent is very complicated in many cases. Thus, phototoxicity is possible to be just a minor inconvenience regarding the importance and severity of the other side-reactions but studies should be made in order to evaluate the possible contribution of photoactive intermediates in the therapeutic or toxic activities of drugs potentially precursors of arenediazonium ions.

CONCLUDING REMARK

In the present paper, a review has been made in relation with the mechanisms involved in drug phototoxicity. As can be easily understood, it is not conceivable to include all of the results obtained about this subject even being limited to recent years. Thus, only relevant data have been picked up from the literature with regard to mechanistic aspects associated to drug-induced phototoxicity.

The current status in this field appears to be characterized by a significant dispersion in relation with methodology, results and assessment of these results. This situation could be parallel to the difficulty to obtain reliable data from animal or human tests as well as from clinical epidemiologic studies (Spielmann et al., 1995).

With regard to the mechanistic pathways, it is accepted basically the four paths as main routes for phototoxic reactions, namely singlet oxygen formation, radical formation, covalent photobinding and production of photoproducts in decomposition reaction. However, several possibilities combinating these elements along with the inclusion of unusual routes composes a very complicated picture. Thus, any attempt to reduce the mechanistic aspects to a formal assortment becomes a rough approach to the experimental behaviour. The differences found in the phototoxic mechanisms appears linked, in principle, to structural features which may differ from one molecule to other even in the molecules pertaining to the same chemical group. In fact, structural factors determine the ability to absorb radiation, the probability to reach triplet state, the bonding breakage in homolytic or heterolytic processes, the stability of photoproducts, etc. Nevertheless, significant mechanistic variations must be expected depending on the environment in which the photosensitization occurs, the localization of the photosensitizers or the accesibility of the targets. These circumstances have been pointed out in the recent literature (Martínez et al., 1998) (Bilski et al., 1998) (Snyder et al., 1999) (Ouedraogo et al., 1999) (Aveline et al., 1999). Likewise, it is worth noting that the phototoxic effects could be enhanced or quenched in particular cases as a result of interferences coming from medication, individual susceptibility, etc.

In relation to the drugs which could act potentially as arenediazonium precursors a limited information about their phototoxicity is found in the literature although possible unwanted interferences could be expected.

REFERENCES


Ars Pharmaceutica, 41:1; 27-46, 2000

Ars Pharmaceutica. 41:1; 27-46, 2000


Lawson, T.; Chauhan, Y. (1985) Metabolism of arylhyrazines by mouse liver mixed-function oxidases


Biochem Pharmacol. 31, 1257-1266


Ars Pharmaceutica, 41:1; 27-46, 2000


Quintero, B.; Morales, J.J.; Quirós, M.; Martínez-Puenputedura, M.I.; Cabeza, M.C. Diazoniumation of p-hydroxybenzenediazonium ion in a neutral aqueous medium (Submitted for publication)


